- Home
- RYOJ vs GDTC Comparison
RYOJ vs GDTC Comparison
Compare RYOJ & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RYOJ
- GDTC
- Stock Information
- Founded
- RYOJ 2015
- GDTC 2018
- Country
- RYOJ Japan
- GDTC Singapore
- Employees
- RYOJ N/A
- GDTC N/A
- Industry
- RYOJ Professional Services
- GDTC Biotechnology: Pharmaceutical Preparations
- Sector
- RYOJ Consumer Discretionary
- GDTC Health Care
- Exchange
- RYOJ Nasdaq
- GDTC Nasdaq
- Market Cap
- RYOJ 24.2M
- GDTC 24.8M
- IPO Year
- RYOJ 2025
- GDTC 2023
- Fundamental
- Price
- RYOJ $4.18
- GDTC $1.92
- Analyst Decision
- RYOJ
- GDTC
- Analyst Count
- RYOJ 0
- GDTC 0
- Target Price
- RYOJ N/A
- GDTC N/A
- AVG Volume (30 Days)
- RYOJ 1.3M
- GDTC 190.4K
- Earning Date
- RYOJ 11-28-2025
- GDTC 01-01-0001
- Dividend Yield
- RYOJ N/A
- GDTC N/A
- EPS Growth
- RYOJ 72.91
- GDTC N/A
- EPS
- RYOJ 0.13
- GDTC N/A
- Revenue
- RYOJ $11,576,848.00
- GDTC $573,193.00
- Revenue This Year
- RYOJ N/A
- GDTC $5.37
- Revenue Next Year
- RYOJ N/A
- GDTC N/A
- P/E Ratio
- RYOJ $32.57
- GDTC N/A
- Revenue Growth
- RYOJ 5.60
- GDTC 63.03
- 52 Week Low
- RYOJ $1.81
- GDTC $1.65
- 52 Week High
- RYOJ $11.43
- GDTC $4.05
- Technical
- Relative Strength Index (RSI)
- RYOJ N/A
- GDTC 45.37
- Support Level
- RYOJ N/A
- GDTC $1.84
- Resistance Level
- RYOJ N/A
- GDTC $2.02
- Average True Range (ATR)
- RYOJ 0.00
- GDTC 0.22
- MACD
- RYOJ 0.00
- GDTC -0.03
- Stochastic Oscillator
- RYOJ 0.00
- GDTC 22.54
About RYOJ rYojbaba Co. Ltd. Common Shares
rYojbaba Co Ltd is engaged in improving and restoring physical and mental health diminished by work-related stress through consulting and health services. The company provides consulting services to labor unions and companies wishing to build constructive relationships with labor unions and health services to osteopathic clinics and osteopathic beauty salons to alleviate physical ailments created by work-related stress.
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.